Sucampo Pharmaceuticals — Investor Presentation (May 2015)
19 slides from Sucampo Pharmaceuticals's investor presentation, May 20, 2015
Slide 1: Sucampo Pharmaceuticals, Inc.
= Sucampo Pharmaceuticals, Inc. BS Global fealtiicals Stan Miele President, ¢ $ sucAMPO ‘The Science of Innovation
Slide 2: Forward-Looking Statements
Forward-Looking Statements litigation andior regulatory actions. Which Sucampo incorporates by reference. @ sucAMPO 2 é ‘The Selence of Innovation
Slide 3: Sucampo Overview
Sucampo Overview = Sucampo i lobal biophai y built on the ongoing pursuit of scientific innovation and an unwavering passion for improving the lives of patients = Proven Ff successful ical product 1 = AMITIZA® i: gship product: differentiated profile in an attractive hat wit t need cy g foundation =
Slide 4: Clear Strategy to Methodically Build a Leading Bio/Pharma Company
Revenue & Market Value = Focus efforts strengthen vera capabilities + Team + Development capability Secure and grow AMITIZA, revenues + Efforts to ores consistent and stant rowth + Global partn ripe @ cnacta rete of patent litigatio Optimize investment in current ici + Life cycle management (LCM) +
Slide 5: AMITIZA (lubiprostone)
| = “2 ° amitiza lubiprostone e $ sucamPo ‘The Science of Innovation
Slide 6: AMITIZA is a Unique and Highly-Differentiated Product
AMITIZA is a Unique and Highly-Differentiated»Product 3 patient types Ww . * CIC: Chronic Idiopathic Constipation * IBS-C: * OIC: = Only i 1. Increases intestinal fluid secretion i function Key product characteristics Locally- Ie} . safety pro’ * No black oom warning $ sUCAMPO é ‘The Selence of Inno
Slide 7: Brand TRx by Category
Tarte warty Annual: (Cituceh, Saline lx & mineral ol 50M TRx & Sanefiser) _(orbtol& Mik of Mag} $4.48 Linaclotide \ Fit Enomas (1%) san \, alr — Heo 6 ‘ ee RON leritant- ‘stimulant lax (ExLax, Dulcoiax) Bentyl (other IBS) ‘Stool softener ‘without stimulant laxatives (Colace) Osmi Prep, PEG preps nal
Slide 8: TRx Scripts
TRx Scripts 1,350,000 9 1,300,000 1,250,000 1,200,000 1,150,000 YTD growth 6% 2012 20132014 TRx Scripts’ 600,000 7,652 2012 aUnits “Based on Management assumption of 4 capsules portrx 4,241,304 489,843, 2013, 2014 $ SUCAMPO ‘The Science of Innovation
Slide 9: Levers Will Drive AMITIZA Outsized Growth
evers Will Drive AMITIZA-Outsized, Growth v Underpenetrated markets with unsatisfied patients Expanded Takeda agreement Physician Targeting prc 4A & OR OIC driving = 30% of brand sales v Yearly Increases v Takeda Tene onatee + Net sales ts revenue spit on brand lubiprost incl. LO Y Agreement with Pa
Slide 10: New Market Opportunities
New Market Opportunities U.K. cic; OIC under review Switzerland us. CIC and OIC CIC, IBS-C and oic Latin America TBD Takeda is #1 Gl company world wide Takeda has rights to all markets except Japan (Mylan) and China Py SUCAMPO reece congeim tn us, oun cea ay foun uaewory. Nenenenenrspon rears. coin
Slide 11: AMITIZA Life Cycle Management
AMITIZA Life Cycle Management 1. New Formulation capsules, or naso-gastric tube fed patients swallowing pills + Next step: Phase 3 commence 2H 2015 » US Prevalence: 18% of pediatric population (13.5M) » Unmet need: No FD, * Current formulation: capsule formulation e $ sucamPo ‘The Science of Innovat
Slide 12: Sucampo
¢ $ sucAMPO ‘The Science of Innovation
Slide 13: At-A-Glance: Sucampo Pipeline
At-A-Glance: Sucampo Pipeline [ CLINICAL FOCUS | ‘STAGE OF CLINICAL DEVELOPMENT TIMELINE TARGETS Leap comPouNnDs [ress punse 2 punses Lubjprostone —Pediatric Functional Constipation (6 years-17 years) Lifecyele Management Lubjprostone —Altemate Formulation — Pediatric Functional Constipation (Gmonth
Slide 14: Supplementing Existing Pipeline
Supplementing Existing Pipeline e $ sucamPo ii ‘The Science of Innovation
Slide 15: Sucampo
¢ $ sucAMPO ‘The Science of Innovation
Slide 16: Total Revenue
Total Revenue AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes} WV Notes Payable Total Revenue AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes): Net Income $25M - $30M. | EPS | $0.55 - $0.65 | $ sucAMPO ‘6 ‘The Science of Innovation
Slide 17: Upcoming Milestones
Upcoming Milestones vent Global partnership agreement for AMITIZA. v Updated on AMITIZA alternate formulation and PFC development T Filed AMITIZA for approval in Canada T Initiated MRP to secure approval for AMITIZA (CIC) in additi E kets Ni ‘Decision made on ion channel activator program for LSS T
Slide 18: Investment Highlights
Investment Highlights = Lead pl with a ee unmet pele BI hi ide alobal Wh and.del teed revenue pls bn = Multiple | ilabl dri inable long term growth 7 i i foundation i i maximizes franchise value = Strong financial perf it! heet and cash position = Deep with p p product development ¢$ SuCAMPO é ‘The
Slide 19: Sucampo
¢ $ sucAMPO ‘The Science of Innovation
Sucampo Pharmaceuticals — Investor Presentation (May 2015) on 6ix